RxDoctor Payments Data

Jasmine Spearman, NP

Nurse Practitioner · Baton Rouge, LANPI 1477215168

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,130 of the $13,130 with a category attached, or 77.2%. 57 manufacturers reported payments, led by Merck at 29.0% of the total. Reporting peaked in 2023 at $4,490 and has fallen 52.2% since, to $2,147 in 2025. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,130in general payments, 2019–2025

Across 478 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4K
  • AstraZeneca$1K
  • Daiichi Sankyo Inc.$1K
  • Novartis$1K
  • Gilead$645
  • Eisai Inc.$597
  • plus $5K from 51 others

What the payments were for

  • Speaking & faculty fees$2,73021%
  • Travel & lodging$1751%
  • Food & beverage$10,13077%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,130 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,523
Medicare patients
97
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib12$197,614
XtandiEnzalutamide11$148,198
EliquisApixaban24$15,546
Letrozole70$1,875
Ondansetron OdtOndansetron111$1,710
Promethazine Hcl79$546
Tamoxifen Citrate21$515
Lidocaine-PrilocaineLidocaine/Prilocaine38$510
Fluconazole13$464
Mirtazapine23$425
Anastrozole31$356
Dexamethasone17$202
Gabapentin20$174
Potassium Chloride48$126
Levofloxacin12$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$1,081$197,61412 claims
Astellas Pharma US IncXtandi$240$148,19811 claims
PfizerEliquis$565$15,54624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →